developing lsc-targeting agents in aml: progress and current therapeutic capacity
Published 4 months ago • 119 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
2:26
insights into the future of aml therapy: the increasing use of targeted agents
-
2:57
the importance of analyzing cytogenetic risk in patients with aml undergoing haploidentical sct
-
1:02
the impact of sequencing in aml
-
4:31
limitations of targeted therapy for aml
-
6:50
improving the management of patients with newly diagnosed aml presenting with hyperleukocytosis
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis
-
1:03
personalizing aml treatment by targeting mrd mutations
-
2:25
the importance of molecular characterization and precision medicine in aml
-
4:48
understanding acute myeloid leukemia - part 1
-
2:19
acute myeloid leukemia - causes, symptoms, treatments & more…
-
3:17
symptoms and treatment options for blood cancer – animation
-
5:35
clinical and prognostic significance of aberrant t-cell marker expression in aml
-
1:36
targeted therapy for aml
-
2:34
the evolution of the aml treatment paradigm
-
2:45
continuity of care for patients with hematological predispositions to aml
-
3:37
the future of aml treatment
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
2:48
key targets and the future of immunotherapy in aml
-
2:09
advances in the management of fit adults with aml
-
1:07
an insight into the pathogenesis of aml
-
1:42
novel treatment combinations in aml: what’s to come?
-
1:21
trends in allosct for good-risk aml: a longitudinal study